3,492.00
-80(-2.24%)
Currency In JPY
Address
3-5-1, Nihonbashi-honcho
Tokyo, 103-8426
Japan
Phone
81 3 6225 1111
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
18726
First IPO Date
January 04, 2000
| Name | Title | Pay | Year Born |
| Mr. Hiroyuki Okuzawa | President, Chief Executive Officer & Representative Director | 215M | 1962 |
| Mr. Sunao Manabe D.V.M., Ph.D. | Executive Chairperson | 302M | 1954 |
| Naoto Tsukaguchi | Executive Officer, Head of Global Legal & IP, GC | 0 | N/A |
| Tomohiro Kodama | Corporate Officer and Head of Finance & Acc. Dept, Global Corporate Planning & Management | 0 | N/A |
| Matt Allegrucci | Head of Global Compliance & Risk Management and Chief Compliance Officer | 0 | N/A |
| Kentaro Asakura | Corporate Officer, Head of Corporate Communications Deptt, Global Corporate Planning & Mngmt | 0 | N/A |
| Mr. Takashi Matsumoto | Senior Executive Officer, Head of Global HR, CHRO & Director | 0 | 1964 |
| Mr. Koji Ogawa | Senior Exe. Off., Head of Corporate Planning & Mgt. and Chief Financial Officer | 0 | N/A |
| Hiroto Kashiwase | Executive Officer & Head of Technology Division | 0 | N/A |
| Ms. Marielle Cohard-Radice M.D. | Global Head of Development | 0 | N/A |
Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.
